1. Home
  2. MLYS vs DAO Comparison

MLYS vs DAO Comparison

Compare MLYS & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • DAO
  • Stock Information
  • Founded
  • MLYS 2019
  • DAO 2006
  • Country
  • MLYS United States
  • DAO China
  • Employees
  • MLYS N/A
  • DAO N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • DAO Other Consumer Services
  • Sector
  • MLYS Health Care
  • DAO Real Estate
  • Exchange
  • MLYS Nasdaq
  • DAO Nasdaq
  • Market Cap
  • MLYS 609.7M
  • DAO 578.5M
  • IPO Year
  • MLYS 2023
  • DAO 2019
  • Fundamental
  • Price
  • MLYS $12.34
  • DAO $7.06
  • Analyst Decision
  • MLYS Strong Buy
  • DAO
  • Analyst Count
  • MLYS 2
  • DAO 0
  • Target Price
  • MLYS $30.00
  • DAO N/A
  • AVG Volume (30 Days)
  • MLYS 163.5K
  • DAO 195.0K
  • Earning Date
  • MLYS 11-11-2024
  • DAO 11-14-2024
  • Dividend Yield
  • MLYS N/A
  • DAO N/A
  • EPS Growth
  • MLYS N/A
  • DAO N/A
  • EPS
  • MLYS N/A
  • DAO 0.07
  • Revenue
  • MLYS N/A
  • DAO $822,103,071.00
  • Revenue This Year
  • MLYS N/A
  • DAO $11.69
  • Revenue Next Year
  • MLYS N/A
  • DAO $14.01
  • P/E Ratio
  • MLYS N/A
  • DAO $106.26
  • Revenue Growth
  • MLYS N/A
  • DAO 7.53
  • 52 Week Low
  • MLYS $7.37
  • DAO $2.86
  • 52 Week High
  • MLYS $16.91
  • DAO $8.01
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 47.76
  • DAO 58.69
  • Support Level
  • MLYS $11.19
  • DAO $6.61
  • Resistance Level
  • MLYS $12.57
  • DAO $8.01
  • Average True Range (ATR)
  • MLYS 0.80
  • DAO 0.49
  • MACD
  • MLYS -0.06
  • DAO -0.05
  • Stochastic Oscillator
  • MLYS 43.07
  • DAO 51.77

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About DAO Youdao Inc. each representing one

Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and Youdao Pocket Translator.

Share on Social Networks: